NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: MEDICAPQ · data 2026-10-31
Medi-Caps Ltd.
In plain words
Price: 32.9% below its 52-week high of ₹36.8.
Delivery: 71.2% of traded shares were kept for delivery over the last 10 sessions, against 76.7% over the last 23.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹13 cr |
| Net profit (last 12 months) | ₹-2 cr |
| Sales growth, 3 years (yearly) | -36.9% |
| Profit growth, 3 years (yearly) | — |
At a glance
ROE -2.6%, ROCE -9.5%, operating margin -77.2%: how much profit it earns on the money it uses.
Debt/equity 0.00, Profit growth — and sales growth -36.9% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- Low return on equity (-2.6%).
- Thin operating margin (-77.2%).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Medi-Caps Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0, so it carries little or no borrowing on the balance sheet.
What is the 52-week high and low of Medi-Caps Ltd.?
The 52-week high is ₹36.8 and the 52-week low is ₹20.33.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Medi-Caps Ltd. | ₹24.69 | ₹30 cr | — | — | -2.6% | -9.5% | 0 | -5.8% |
| Vivimed Labs Limited | ₹5.53 | ₹51 cr | — | — | — | -43.6% | — | +5.3% |
| Biofil Chemicals & Pharmaceuticals Ltd. | ₹28.68 | ₹47 cr | 96.4 | — | 13.8% | 1.8% | 0.14 | -27.5% |
| Mangalam Drugs & Organics Ltd. | ₹28.61 | ₹46 cr | — | — | -35.2% | -22.8% | 1.08 | -58.2% |
| Medicamen Organics Ltd. | ₹26.5 | ₹39 cr | — | — | -13.7% | -15% | 0.5 | -24.6% |
| Lasa Supergenerics Ltd. | ₹4.67 | ₹25 cr | — | — | -51.1% | -27% | 0.2 | -55.1% |
Compare MEDICAPQ with VIVIMEDLAB in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open MEDICAPQ in NSE Scanner →